Session Details
[1AT1-10]8. Biology of Diseases Ⅰ
Tue. Dec 1, 2026 9:00 AM - 11:00 AM JST
Tue. Dec 1, 2026 12:00 AM - 2:00 AM UTC
Tue. Dec 1, 2026 12:00 AM - 2:00 AM UTC
Room 10 (Conference Center 4F 413)
Chairs: Noriko Fujiwara (Hyogo Medical University), Takeharu Sakamoto (Kansai Medical University)
Presentation Time: 10 minutes (8 minutes for the presentation, 1 minute 30 seconds for discussion, and 30 seconds for transition)
[1AT1-10-01(1P-0522)]Development of a therapeutic approach using novel cccDNA-binding repeat RNA toward the functional cure of hepatitis B virus
○Takeshi Kamakura1, Kaku Goto1, Keita Yamamoto2, Susumu Goyama2, Toshitsugu Fujita3, Hodaka Fujii3, Yuuya Kasahara4,5, Motoyuki Otsuka6, Kazuhiko Maeda7,8, Shizuo Akira7,8, Ai Kotani1 (1. RIMD, Reg. of Infect. Cancer, Univ. of Osaka, 2. Univ. of Tokyo, 3. Hirosaki Univ., 4. NIBN, 5. Grad. Sch. of Pharm., Univ. of Osaka, 6. Okayama Univ., 7. IFReC, Host Defnese, Univ. of Osaka, 8. RIMD, Host Defnese, Univ. of Osaka)
[1AT1-10-02(1P-0544)]Sex differences in MASH pathology and their molecular mechanisms in a Down syndrome model
○Jing He1, Hiro Kohda1, Miyako Tanaka1, Takayoshi Suganami1 (1. Nagoya Univ.)
[1AT1-10-03(1P-0455)]PRAME drives BCG resistance in non-muscle-invasive bladder cancer by suppressing the RIG-I–MAVS–IRF3–type I interferon axis
○Miyu Azuma1, Moritoshi Sakamoto1,2, Kazuki Nishimura1,2, Ryoichi Maenosono1,2, Maiko Seki1, Kensuke Hirosuna1,2, Masahiko Ajiro1, Asuka Kawachi1, Junko Mukohyama1,3, Takuya Tsujino1,2, Mitsuaki Ishida4, Kazumasa Komura5, Haruhito Azuma2, Akihide Yoshimi1 (1. Division of Cancer RNA Research, National Cancer Center Research Institute, 2. Department of Urology, Osaka Medical and Pharmaceutical University , 3. Department of Surgery, The Institute of Medical Science, The University of Tokyo, 4. Department of Pathology, Osaka Medical and Pharmaceutical University, 5. Department of Urology, Kawasaki Medical School)
[1AT1-10-04(1P-0458)]Semaphorin 3F inhibits breast cancer metastasis by regulating the Akt-mTOR and TGFβ signaling pathways via neuropilin-2
○Hironao Nakayama1,2,3, Masako Nakahara1, Chiaki Kusumoto1, Shigeki Higashiyama2,3,4 (1. Dept of Med Sci & Tech, Hiroshima Int Univ, 2. Dept of Biochem & Mol Gene, Ehime Univ, 3. Div of Cell Growth & Tumor Reg, PROS, Ehime Univ, 4. Dept of Oncogenesis & Growth Reg, Osaka Int Cancer Inst)
[1AT1-10-05(1P-0548)]TEAD Inhibition Reprograms Hepatic Stellate Cell Subpopulations to Attenuate Fibrosis and Restore Liver Function
○Yoshinobu Saito1, Ryohei Yamauchi1, Hayato Hikita1, Takahiro Kodama1 (1. Univ. of Osaka)
[1AT1-10-06(1P-0575)]Identification of a Direct NRF2 Transcriptional Network Linking Autophagy and Neuroinflammation in Human Microglia
○Ching Tung Chu1, Akira Uruno1, Takafumi Suzuki1,3, Keiko Taguchi1, Liam Baird1, Fumiki Katsuoka2,3, Masayuki Yamamoto1 (1. Department of Biochemistry and Molecular Biology, Tohoku Medical Megabank Organization, Tohoku University, 2. Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, 3. Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University)
[1AT1-10-07(1P-0528)]An endonuclease inhibitor unlocking the PA-X shutoff mechanism and viral RNA evasion in influenza A virus
○Kohei Oishi1,2, Kaori Sano1,2, Seiya Yamayoshi1,3, Kei Miyakawa1,2, Hideki Hasegawa1,2, Yoshihiro Kawaoka1,3,4 (1. Japan Institute for Health Security, 2. Hokkaido University, 3. University of Tokyo, 4. University of Wisconsin-Madison)
[1AT1-10-08(1P-0576)]Elucidating the Molecular Basis of Reprogramming-Induced Senescent Cell Rejuvenation
○Yuta Moriguchi1,2, Soichiro Kumamoto2, Yasuhiro Nakano2,3, Tomoaki Hishida4, Yoshikazu Johmura2,3 (1. Graduate School of Natural Science and Technology, Kanazawa University, 2. Cancer Research Institute, Kanazawa University, 3. Institute for Frontier Science Initiative, Kanazawa University, 4. Faculty of Pharmacy, Osaka Medical and Pharmaceutical University)
[1AT1-10-09(1P-0549)]SARM1-mediated organ-selective control of hepatic lipid accumulation and tissue metabolic decoupling in obesity
○Ryoichi Sugisawa1, Satoshi Miyanaga2, Naofumi Tomimoto1, Akiyoshi Komuro1, Takeshi Ueda1, Andrew Bowie3, Hitoshi Okada1 (1. Kindai Univ., 2. Kindai Univ. , 3. Trinity College Dublin)
[1AT1-10-10(1P-0502)]Analysis of Anti-inflammatory Effects of Vitamin D3 Metabolite 24R,25-dihydroxyvitamin D3
○Sakura Miyama1, Michihiro Takahama1, Kazuo Harada1,2,3, Hidetaka Kosako4, Naoki Takemura1, Tatsuya Saitoh1,5,6 (1. Grad. Sch. Pharm. Sci., Univ. of Osaka, 2. Grad. Sch. Med., Univ. of Osaka, 3. Grad. Sch. Eng., Univ. of Osaka, 4. Inst. Adv. Med. Sci., Tokushima Univ., 5. Global Ctr., Med. Eng. Inform., Univ. of Osaka, 6. CiDER, Univ. of Osaka)
[1AT1-10-11(1P-0467)]Targeting TRPC6 by Genetic Silencing and Larixyl Acetate Suppresses Bladder Cancer Cell Motility, Invasion, and Angiogenic Signaling
○Chien Rui Lai1, Ying Chen1, Tzu-Min Chen1,2, Yi-Hsuan Lin3, Sheng-Tang Wu4, Chien-Chang Kao4 (1. Department of Biology and Anatomy, National Defense Medical University, Taipei, Taiwan., 2. Department of Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan., 3. Department of Digital Medical Center, Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan., 4. Department of Surgery, Division of Urology, Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan.)
[1AT1-10-12(1P-0582)]Mitochondrial genome replacement restores metabolic flexibility in aged T cells
○Fumiya Teruyama1,2, Toshihiko Taya2, Akira Shikuma2, Satoaki Matoba2, Kentaro Numajiri3, Sayoko Umetani3, Yutong Chen4, Amnon Peled5, Eithan Galun5, Nimer Assy6, Aviad Zick7, Silvia Noiman8, Dayana Michel8, Dori Pelled8, Taro Inaba9, Kenji Chamoto10, Satoshi Gojo1 (1. Kyoto Pref. Univ. of Med., 2. Dept. Cardiovasc. Med., Grad. Sch. Med., Kyoto Pref. Univ. of Med., 3. Bio Sci. & Eng. Labs., FUJIFILM Corp., 4. Div. Immunol. Genomic Med., Ctr. Cancer Immunother. Immunobiol., Grad. Sch. Med., Kyoto Univ., 5. Hadassah Hebrew Univ. Hospital, 6. Dept. Internal Med., Galilee Med. Ctr. Hosp., 7. Sharett Inst. Oncol., Hadassah Med. Ctr., Fac. Med., Hebrew Univ. Jerusalem, 8. IMEL Biotherapeutics, Inc., 9. IMEL Japan, Inc., 10. Div. Cancer Immune Regul., Ctr. Cancer Immunother. Immunobiol., Grad. Sch. Med., Kyoto Univ.)
